LeonaBio, formerly Athira Pharma, has changed its name and ticker symbol to align with its acquisition of rights to develop and commercialize lasofoxifene for metastatic breast cancer. The company’s lead drug candidates, lasofoxifene and ATH-1105, are in late-stage development for metastatic breast cancer and ALS. LeonaBio recently secured an exclusive global license for lasofoxifene and raised $90 million in financing to support development through key milestones. The ongoing Phase 3 trial for lasofoxifene is over 50% enrolled, with data expected in mid-2027. LeonaBio aims to deliver innovative therapies to patients in need.

Read more at GlobeNewswire: Athira Pharma Announces Name Change to LeonaBio, Inc. with